coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Middlewood PCN, Cheshire East (LAD) · Health Inequalities Profile

    PCN U28237 · NHS Cheshire and Merseyside Integrated Care Board · 1 GP practice

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    33,569

    Registered population

    54.8% aged 18–64

    28.4%

    Aged 65+

    ICB 19.0% · England 17.9%

    0.6%

    Ethnic minority (non-White)

    0.1% Asian · England 9.6%

    0.0%

    In IMD quintile 1

    ICB 31.9% · England 21.0%

    0

    Core20 residents (est.)

    Resident basis; registered basis 0 · see page 3

    5,971

    Hypertension register

    +6.45% in 3 yrs · England +5.60%

    284

    SMI register

    7.2% of Cheshire East (LAD)'s

    498

    COPD register

    Reviews +4.39% in 3 yrs

    Forecast to 2030

    6,968

    Hypertension patients, 2030

    +997 on today

    65.8%

    QRISK ≥20% on statins, 2030

    +3.43pp over 3 yrs

    7.3%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -9.2%
    Asthma reviews fell while England rose.

    Annual asthma reviews sit at 64.5% (England 65.7%) after falling 9.2% over three years (England +4.4%), leaving about 810 patients unreviewed.

    64.2%
    Blood pressure and lipid control trail England.

    Hypertension control is 64.2% (England 70.3%), QRISK ≥ 20% lipid therapy 58.3% (England 63.6%), and SMI BP checks 73.0% (England 83.4%).

    66.4%
    Non-frail diabetes control and immunisations lead.

    Non-frail diabetes HbA1c control reaches 66.4% (England 57.4%, +10.8% over three years), alongside 96.1% two-dose MMR coverage at age 5 (England 82.8%).

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    Older patients represent 28.4% of the list, above national and borough benchmarks

    Middlewood PCN operates as a single practice (Middlewood Partnership) serving 33,569 registered patients. The PCN has an older demographic profile: 28.4% (9,523 patients) are aged 65+, compared to 22.6% in Cheshire East (LAD), 19.0% in NHS Cheshire and Merseyside Integrated Care Board, and 17.9% in England. Adults aged 18–64 represent 54.8% and children aged 0–17 represent 16.8%. Census area data shows 99.4% White and 0.6% ethnic minority residents (Asian / Asian British 0.1%, Black / African / Caribbean / Black British 0.2%), though Census residence differs from registered list ethnicity.

    Age profile

    0–1716.8%
    18–6454.8%
    65+28.4%

    65+: ICB 19.0%, England 17.9%

    Ethnicity

    White99.4%
    Black0.2%
    Asian0.1%
    Mixed0.1%
    Other0.0%

    Older people · falls rows are Cheshire East (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Cheshire East LA)2,1292,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)84.3%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)66.4%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Cheshire East LA)9391,0219552024/25
    Falls deaths, all ages, per 100,000 (Cheshire East LA)14.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Average IMD decile is 8.8 with 0.0% of patients residing in Core20 areas

    Middlewood PCN records an average IMD decile of 8.8 (Middlewood Partnership records 9.1), against 7.1 in Cheshire East (LAD), 5.2 in NHS Cheshire and Merseyside Integrated Care Board, and 5.5 in England. Across Middlewood Partnership, 0.0% of registered patients live in Core20 areas (0 patients), versus 9.2% in Cheshire East (LAD), 31.9% in the ICB, and 21.0% in England, with 0 of 34 associated LSOAs in deciles 1 or 2. Inequality work may therefore prioritise clinical risk and inclusion groups rather than area deprivation.

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Middlewood0.0% · 0 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    284

    SMI register

    0.83% recorded prevalence

    87

    Learning disability register

    0.26% recorded prevalence

    19

    Care homes, 675 beds

    In the PCN catchment

    8.8%

    Provide unpaid care

    Cheshire East (LAD), Census 2021

    Recorded prevalence trails England for learning disability at 0.3% (87 patients; England 0.6%) and severe mental illness at 0.8% (284 patients; England 1.0%), alongside 19 catchment care homes (675 beds). Cheshire East records 8.8% providing unpaid care and 10 rough sleepers, which cannot be extrapolated locally. Lower recorded prevalence than England benchmarks may reflect case-finding differences, which a register audit against care home records would test.

    Severe mental illness: physical health checks

    Physical health checks for SMI patients show blood pressure checks at 73.0% (England 83.4%), BMI recorded at 66.3% (England 82.1%), and alcohol consumption records at 65.1% (England 81.8%). Shortfalls across checks leave metabolic and cardiovascular risks unaddressed in this cohort.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    5,971

    Hypertension register

    +6.45%

    Register growth, 3 yrs

    Cheshire East (LAD) +6.54% · England +5.60%

    +2.32pp

    BP control, under 80

    ≤140/90 · +1.45pp aged 80+

    +997

    More patients by 2030

    Forecast 6,968 (19.88%)

    Hypertension case-finding and control

    Middlewood PCN records 5,971 hypertension patients (17.5% prevalence, versus 17.3% in Cheshire East (LAD), 16.8% in NHS Cheshire and Merseyside Integrated Care Board, and 15.2% in England). Recent blood pressure checks reach 87.1% (England 90.0%), but patients treated to target sit at 64.2%, trailing Cheshire East (LAD) (69.8%), the ICB (69.1%), and England (70.3%). Control in patients under 80 is 58.8% (England 67.8%), and 74.8% in those aged 80 and over (England 81.2%). An unverified product projection indicates the register could grow by 997 to 6,968 patients by 2030. Blood pressure control trails national benchmarks across age groups, suggesting systematic treatment escalation and home monitoring reviews could improve control.

    Lipids and statins

    Patients with QRISK ≥ 20% on lipid lowering therapy reach 58.3%, trailing Cheshire East (LAD) (61.2%), NHS Cheshire and Merseyside Integrated Care Board (63.2%), and England (63.6%). Coverage among CKD patients is 63.3% (England 70.3%). Fewer at-risk patients receive lipid-lowering therapy than national rates imply, indicating that secondary prevention and high-risk recall audits should be.

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 202661,437£1.90£1.71£1.86£116,730
    Cardiovascular (all), 202587,490£3.69£4.37£3.33£322,838

    For lipid-modifying drugs in 2026, the PCN prescribed 61,437 items at £1.90 each, above Cheshire East (£1.72), the ICB (£1.71), and England (£1.86). This represents £11,673 more than at the ICB's unit cost. Higher unit costs than system comparators indicate an opportunity for clinical pharmacists to review lipid-modifying formulary alignment.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −9.17%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −0.27%

    Asthma prevalence, PCN 3-yr % change

    Asthma reviews fell 9.2% over three years (England +4.4%) to 64.5% (England 65.7%), leaving about 810 of 2,273 register patients unreviewed. COPD prevalence is 1.5% (498 patients) with reviews at 67.9% (England 76.4%). Smoking cessation offers fell 6.3 pp (England +0.1 pp) to 85.8% (England 94.2%), and youth asthma second-hand smoking recording is 64.0% (England 78.8%). Falling review rates indicate structured recall and preventive advice across respiratory conditions require clinical prioritisation.

    Cancer register and children's immunisation

    Cancer prevalence is 5.8% (1,956 patients; England 3.8%). In children, age-5 MMR dose 2 reaches 96.1% (England 82.8%), trailing dose 1 (97.4%) by 1.3 pp but exceeding the 95.0% target. In contrast, 12-month 6-in-1 coverage is 89.8% (England 91.0%), sitting 5.2 pp below the 95.0% coverage target before reaching 94.5% at 24 months. Strengthening first-year recall is required to avoid delays in completing infant primary courses.

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months89.8%

    England 91.0%

    6-in-1 complete primary course at 24 months94.5%

    England 92.2%

    MMR dose 1 at 24 months92.7%

    England 88.3%

    MMR dose 2 at age 596.1%

    England 82.8%

    4-in-1 pre-school booster at age 592.2%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.5%

    Cheshire and Merseyside ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,640

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Cheshire and Merseyside ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%11%2,354
    Breast87.1%85.4%11%2,083
    Prostate52.3%53.2%12%2,037
    Bowel44.9%47.0%16%1,674
    Skin cancer86.9%87.8%21%932

    In 2022, 55.5% of cancers with a known stage in NHS Cheshire and Merseyside ICB (7,482 of 13,490) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.5 pp below the 75.0% national ambition by 2028. Known-stage cases comprised 72.8% of registered cancers. Reaching 75.0% requires about 2,640 extra early-stage diagnoses annually across the ICB. PCN cancer prevalence is 5.8% (1,956 patients). For the PCN, rigorous safety-netting and sustaining screening uptake are crucial to support timely presentation.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    In Jul 2026, East Cheshire NHS Trust achieved 53.4% on the cancer 62-day referral to treatment standard, 31.6 pp below the 85.0% standard, trailing Stockport NHS Foundation Trust (74.7%), Manchester University NHS Foundation Trust (72.8%), the ICB (76.2%), and England (71.2%). The trust met the 28-day faster diagnosis standard at 81.1% (standard 75.0%) and the 31-day standard at 96.3% (standard 96.0%). Six-week diagnostic waits stood at 16.2% overall, though MRI waits reached 26.6% (Stockport 1.4%). Prolonged treatment backlogs at the main acute provider may delay definitive care.

    Pathways within standard (%)East CheshireStockportManchesterCheshire and Merseyside ICBEngland
    28-day faster diagnosis (75%)81.0883.2180.0677.2579.32
    31-day treatment (96%)96.3097.3992.5495.7192.50
    62-day referral to treatment (85%)53.4174.6772.8576.2371.16
    Diagnostic waits over 6 weeks (%)East CheshireStockportManchesterEngland
    MRI26.621.4111.6821.40
    CT11.492.9314.669.92
    Echocardiography26.2417.464.9128.48
    Colonoscopy10.855.534.5130.83
    Gastroscopy10.255.3129.3529.02
    All 15 DM01 tests16.1714.088.9823.14
    Community services activityCheshire East residentsCheshire and Merseyside ICB
    Care contacts72,825541,280
    Referrals18,28097,150
    Patients with a contact21,910146,240

    Community services (residents of Cheshire East), Jun 2026 (provisional). In Jun 2026, Cheshire East residents accounted for 72,825 community care contacts across 21,910 patients, within 541,280 contacts across NHS Cheshire and Merseyside Integrated Care Board. Adults aged 65+ represented 60.8% of borough contacts (44,295 contacts). Borough referrals totalled 18,280 across 12,885 patients. High community service use is consistent with the PCN's older demographic profile.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Middlewood Partnership achieved 80.0% good patient experience while clinical QOF achievement trailed England

    In 2025/26, Middlewood Partnership attained 89.6% overall QOF points (England 92.5%). Clinical-domain achievement reached 88.4%, trailing England's 97.1%, whereas vaccination and immunisation reached 91.9% (England 55.2%). Personalised care adjustments across all domains were 7.0% (England 10.0%). Clinical achievement shortfalls alongside lower adjustment rates highlight an opportunity to review chronic disease pathways.

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Middlewood1720.058.4%76.4%80.0%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNCheshire East (LAD)AssetPCNCheshire East (LAD)
    Care homes (catchment)19 (675 beds)n/aSchools (catchment)40n/a
    Children's centres114Places of worship29272
    Libraries316Day centres (VCS)n/a1
    Children and young people (VCS)n/a1Carers support groups (VCS)n/a1
    Primary schools (LA maintained)1241Primary academies978
    Special schoolsn/a5

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma review recall

    Asthma review completion is 64.5% (England 65.7%) and fell 9.2% over three years (England +4.4%), leaving about 810 of 2,273 register patients unreviewed. For discussion: Middlewood Partnership could run a single-template recall search and offer flexible review slots alongside inhaler prescribing checks. Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension and lipid therapy escalation

    Across 5,971 hypertension patients, treatment to target is 64.2% (England 70.3%; under-80s 58.8% vs 67.8%), and QRISK ≥ 20% lipid therapy is 58.3% (England 63.6%). For discussion: the PCN could establish pharmacist-led hypertension titration and high-risk QRISK lipid initiation clinics using structured searches. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Learning disability register validation

    Recorded learning disability prevalence is 0.3% (87 of 33,569 patients) after falling 2.9% (England +5.4%), a modelled gap of +67 to +110 against borough (0.5%) and England (0.6%). For discussion: Middlewood Partnership could audit diagnostic codes and cross-check the register against social-care and care-home records where permitted. Low cost, quick to run.

    Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.

    Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Older adult anticipatory care review (p2)Aged 65+Neighbourhood health framework · NHS vaccination strategyPCN
    SMI physical health check recall (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension treatment escalation audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Infant immunisation recall review (p6)6-in-1 coverage at 12 months10YHP sickness to prevention · 95% targetPCN
    Early diagnosis safety netting audit (p7)Cancers diagnosed at stage 1 or 2 (All cancer sites)—ICB
    Telephone queue retention audit (p9)GPPS callers held in a queue who waited until someone answered—Practice
    Option 1 · Structured asthma review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs)Core20PLUS5 respiratoryPCN
    Option 2 · Hypertension and lipid therapy escalation (p12)Hypertension register · Hypertension patients treated to target · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Learning disability register validation (p12)Learning disability register · Learning disability: QOF prevalence · Registered population75% annual health checks (Network Contract DES) · Oliver McGowanPCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15